This blog post was first published in Bridge Michigan on May 28, 2024 by Quinn Nichols, Nicole Koonce, and Allison Hardt under the title: Michigan has a chance to learn from California’s public pharma initiative. Read more
T1International and other organisations shared a letter today with Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, urging that the World Health Organization reject any funding directly or indirectly from the pharmaceutical industry. The entity already rejects funding from the tobacco and formula milk industry. The letter also asks WHO to push the pharmaceutical industry to lower prices and create sustainable solutions, and to practise more transparency and accountability to the global community that the entity exists to serve. Read more
We are writing to propose WHO action items aimed at addressing meaningful engagement with people living with diabetes in the global coverage targets for diabetes. Read more
T1International advocates, Jesús Morales Sánchez (Communities of Color Working Group Co-Leader), Kristen Whitney Daniels (Federal Working Group Co-Leader), Lib Gatti (USA Advocacy Manager), and Shaina Kasper (Policy and Advocacy Director), were honored to be invited to a recent event at the White House focused on lowering healthcare costs. The event celebrated the success of the access to medicines movement in achieving a $35 monthly cap on out-of-pocket costs for insulin for Medicare Part D beneficiaries, allowing Medicare to negotiate drug prices directly with pharmaceutical companies, and more. Read more
On March 16, 2024, hundreds of #insulin4all advocates participated in over a dozen events across the globe calling for insulin access and affordability as part of the Global Day of Action for #insulin4all, sharing their stories on the critical need for insulin equity now. Read more
As a person living with type 1 diabetes who has been involved with T1International since 2019, I’m so proud to step into the role of Board Chair of Trustees this year. I believe in this organisation and this cause deeply because it is personal to me. I live with the ups and downs of diabetes, and I believe in health justice for everyone who is faced with this condition worldwide. Read more
As we begin 2024 and think about the plans for T1International this year and beyond, I wanted to share a personal update that is also a big organisational update. After over a decade of leading T1International, the time has come for me to transition from my role as Executive Director by the end of 2024. This decision was not made lightly. Read more
The #insulin4all movement has had some major victories lately. For example, Medicare beneficiaries can access $35 copays for some insulins. The list price of insulin went down for nine insulins. Over half of the states in the USA have passed some form of insulin copay cap. These victories were hard fought by #insulin4all advocates over the past decade. But we’re not celebrating the much heralded $35 insulin cap for all. Because it’s not true.
Read more
Only eight days of National Diabetes Awareness Month had passed this November when pharmaceutical company Novo Nordisk announced it would be pulling Levemir, a long-acting insulin that millions of insulin-dependent diabetic patients depend on, from the U.S. market. Read more
To kick off Diabetes Awareness Month, the Global Diabetes compact held a two-day meeting where T1International and 35 other organisations in over 25 countries presented the goal of the Fight for Five campaign. We showed the depth and breadth of support for this campaign not only through stories of patients most impacted by lack of affordable and accessible insulin in their home countries, but also by the number of organisations that support a better world for people with diabetes. Read more